spacer
home > epc > spring 2009 > the value proposition
PUBLICATIONS
European Pharmaceutical Contractor

The Value Proposition

Pharmaceutical and biotech companies are increasingly interested in the use of ‘adaptive’ clinical trials to improve the process of drug development. By an ‘adaptive trial’, we mean a trial that is designed from the outset to review key response data as we collect it, and carry out certain pre-specified adaptations in the light of what we learn.

In large confirmatory trials, regulatory concerns will limit adaptations that can be considered to actions such as stopping the trial early, performing a sample size re-assessment or dropping a treatment arm. In early phase trials, frequent adaptation and a wider scope for adaptation are permitted, for instance: frequent optimisation of the probabilities of adaptation to the different treatment arms; more frequent interims to choose to drop or add treatment arms or to stop the trial; modification of inclusion and exclusion criteria to drop patient subpopulations from the study or restrict the study to a sub-population.

 


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Tom Parke joined Tessella in 1996, and has worked on supporting adaptive clinical trials since 1998. He managed the development of the system that allowed Pfizer to run their groundbreaking ASTIN trial, and has worked on numerous further dose response adaptive trials. He has overseen the development of algorithms, simulation tools and systems to support adaptive trials, as well as integrating adaptive algorithms with existing central randomisation and electronic data capture systems. Whilst currently working on his twelfth dose-response adaptive trial, Tom is consulting with a number of international pharmaceutical companies, helping them to define the software systems they require to run adaptive clinical trials.

spacer
Tom Parke
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Pharmaceuticals and Healthcare Products

Turkish Cargo

Pharmaceuticals are requiring safe and reliable transportation for being highly temperature sensitive products. Thosepharmaceuticals are; diagnostics, vaccines drugs, sera, plasma, protein clinical trials, biotechnological material, pills and all kind of medicines. Turkish Cargo transports all kind of pharmaceuticals, and has been carrying out its operations of transporting and storing drugs and temperature-sensitive medical supplies successfully and with the experience of 80 years; since 1936.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement